172217-11-7

Basic information

• Product Name: ETHYL 2-AMINO-6-CHLOROBENZOATE
• Synonyms: ETHYL 2-AMINO-6-CHLOROBENZOATE
• CAS NO: 172217-11-7
• Molecular Formula: C₉H₁₀ClNO₂
• Molecular Weight: 199.63
• Mol File: 172217-11-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: ETHYL 2-AMINO-6-CHLOROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-AMINO-6-CHLOROBENZOATE(172217-11-7)
• EPA Substance Registry System: ETHYL 2-AMINO-6-CHLOROBENZOATE(172217-11-7)

Safety Data

• Hazardous Substances Data: 172217-11-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 2-AMINO-6-CHLOROBENZOATE is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its role in this industry is pivotal due to its ability to facilitate the production of a wide array of medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, ETHYL 2-AMINO-6-CHLOROBENZOATE is utilized as an intermediate in the formulation of agrochemicals, playing a crucial part in the creation of products that enhance crop protection and agricultural yield.
Used in Medicinal Chemistry Research:
ETHYL 2-AMINO-6-CHLOROBENZOATE is employed as a building block in the synthesis of bioactive molecules, which are essential for advancing research in medicinal chemistry. Its structural properties make it a valuable component in the design and development of novel compounds with potential therapeutic applications.
Used in Chemical Industry:
ETHYL 2-AMINO-6-CHLOROBENZOATE's wide-ranging applications in the chemical industry are due to its importance in the synthesis of various chemical products, highlighting its multifaceted utility in chemical processes and compound development.

Upstream product

• 172217-16-2 ethyl 2-chloro-6-nitrobenzoate 
• 64-17-5 ethanol 
• 2148-56-3 2-chloro-6-aminobenzoic acid 
• 141-52-6 sodium ethanolate 
• 75-03-6 ethyl iodide 

Downstream Products

• 112270-06-1 ethyl 2-chloro-6-hydroxybenzoate 
• 172217-13-9 ethyl 6-chloro-2-methoxycarbanilate 
• 172217-12-8 ethyl 6-chloro-2-methoxybenzoate 
• 3260-89-7 2-chloro-6-methoxybenzoic acid 
• 379230-45-2 3-allyl-6-chloro-2-hydroxybenzoate 
• 412349-25-8 2-(4-chloro-3-ethoxycarbonyl-2-hydroxyphenyl)acetaldehyde 
• 379230-44-1 ethyl 2-(allyloxy)-6-chlorobenzoate 
• 379230-47-4 6-chloro-1-benzofuran-7-carboxylic acid 
• 379230-43-0 6-chloro-1-benzofuran-7-amine 

Relevant articles and documents

AMPK MODULATORS

The present invention relates to compounds and pharmaceutically acceptable salts, esters and prodrugs of Formula (I) or (II), which are useful as AMPK modulators effective in treating diabetes, obesity and cancer in a subject.

Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src

Deregulated activity of the nonreceptor tyrosine kinase c-Src is believed to result in signal transduction, cytoskeletal and adhesion changes, ultimately promoting a tumor-invasive phenotype. We report here the discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of the c-Src enzyme. Special attention was directed toward finding inhibitors selective against KDR tyrosine kinase in order to ensure that the in vivo profile of a specific Src inhibitor could be determined. The 4-aminobenzodioxole quinazoline series gave compounds with excellent potency and selectivity. The most interesting compounds were evaluated in vivo and displayed good pharmacokinetics following oral dosing. Compounds such as the aminobenzodioxoles were shown to be potent inhibitors of tumor growth in a c-Src-transformed 3T3 xenograft model in vivo, resulting in more than 90% growth inhibition at doses as low as 6 mg/kg po once daily. Src tyrosine kinase inhibitors such as these may provide a novel therapeutic modality for targeting cancer invasion and metastasis.

QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS

The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, m, R1, R2, R3 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease

Quinazoline derivatives with anti-tumour activity

The invention concerns quinazoline derivatives of Formula I wherein each of m, R1, n, R2 and R3 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

Fischer indolization of ethyl pyruvate 2-bis(2-methoxyphenyl)hydrazone and new insight into the mechanism of Fischer indolization. (Fischer indolization and its related compounds. XXVII)

In connection with studies on the direction of cyclization in the Fischer indolization of substituted diphenylhydrazones, the Fischer indolization of ethyl pyruvate 2-bis(2-methoxyphenyl)hydrazone (6) was carried out. The result showed that cyclization in Fischer indolization of diphenylhydrazone does not always proceed to the electron-richer nucleus, but depends on the conformation of the enehydrazine. Thus, the Fischer indolization should proceed via a [3,3] sigmatropic route, with an electronic effect.